Dimerix Receives Innovation Passport and ILAP Designation
Filed with ASX · · 3 pages · English
Earlier from Dimerix
- Dimerix Confirms Phase 3 FSGS Study Design With EMA
- DMX-200 Remains Eligible for Accelerated Approval
- COVID-19 Study Recruits Multiple Patients in Europe
- Major Shareholder Loan for $5 Million
- Clinical Study in Patients with COVID-19 Progresses
Later from Dimerix
- FDA Confirms Phase 3 Study Design in FSGS Kidney Disease
- DMX-200 COVID-19 Study Opens More Sites in Europe and UK
- Successful $20m Placement to Fund Phase 3 Trials
- Response to ASX Query
- SPP and Options Prospectus
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix